In conclusion, we have shown that HDAC inhibitors can be used to increase the replication of an oHSV in breast cancer cells without increasing replication in normal breast epithelial cells, and we have shown that an oHSV-resistant tumor cell line can be made more susceptible to oHSV replication. This evidence concerns the gene HDAC9 and breast cancer.